Indemnity issues may hold up availability of J & J single dose vaccine

While the drug regulator has given a nod to Biological E to manufacture the vaccine at its plant in Telangana, its launch looks unlikely till the government resolves the indemnity issue. “The discussions between the government and the company are ongoing and there is no conclusion yet on the indemnity issue,” said a senior government official on the condition of anonymity.
Source: The Economic Times Healthcare and Biotech News - Category: Pharmaceuticals Source Type: news